Berenberg Bank Begins Coverage on Evotec (NASDAQ:EVO)

Investment analysts at Berenberg Bank began coverage on shares of Evotec (NASDAQ:EVO) in a research report issued on Tuesday, Marketbeat reports. The brokerage set a “buy” rating on the stock.

Several other equities analysts have also recently commented on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Evotec in a research report on Monday, December 29th. Wall Street Zen upgraded Evotec from a “sell” rating to a “hold” rating in a research note on Saturday, January 10th. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Evotec has a consensus rating of “Hold” and a consensus target price of $7.00.

Evotec Trading Down 1.8%

Shares of EVO opened at $3.72 on Tuesday. The company’s 50-day simple moving average is $3.33 and its 200-day simple moving average is $3.55. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.12 and a quick ratio of 2.03. Evotec has a 1 year low of $2.84 and a 1 year high of $4.80.

Institutional Investors Weigh In On Evotec

Several institutional investors have recently modified their holdings of EVO. BNP Paribas Financial Markets increased its holdings in Evotec by 62.2% in the second quarter. BNP Paribas Financial Markets now owns 12,000 shares of the company’s stock valued at $50,000 after buying an additional 4,600 shares during the last quarter. Bank of America Corp DE lifted its holdings in Evotec by 262.5% during the 4th quarter. Bank of America Corp DE now owns 12,828 shares of the company’s stock worth $53,000 after buying an additional 9,289 shares during the last quarter. Valeo Financial Advisors LLC acquired a new position in shares of Evotec during the 2nd quarter worth about $43,000. Thrivent Financial for Lutherans acquired a new position in shares of Evotec during the 3rd quarter worth about $53,000. Finally, XTX Topco Ltd purchased a new position in shares of Evotec in the 2nd quarter valued at about $66,000. 5.81% of the stock is owned by hedge funds and other institutional investors.

About Evotec

Evotec SE (NASDAQ:EVO) is a global biotechnology company headquartered in Hamburg, Germany, specializing in drug discovery and development partnerships. The company leverages its integrated discovery platforms to support pharmaceutical and biotech clients in advancing novel therapies from target identification through preclinical development.

Evotec’s service offering encompasses high-throughput screening, bioanalytics, combinatorial chemistry, structural biology, pharmacology, and computational drug design.